Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000256105 | SCV000322085 | pathogenic | not provided | 2021-11-10 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28529015, 31703437, 32124548, 25326635, 28135719) |
Ambry Genetics | RCV000622880 | SCV000740977 | pathogenic | Inborn genetic diseases | 2022-06-21 | criteria provided, single submitter | clinical testing | The c.3770_3771delAA (p.K1257Rfs*25) alteration, located in exon 9 (coding exon 7) of the ANKRD11 gene, consists of a deletion of 2 nucleotides from position 3770 to 3771, causing a translational frameshift with a predicted alternate stop codon after 25 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration has been reported as a de novo event in multiple unrelated individuals with KBG syndrome (Meyer, 2017; Gnazzo, 2020). Based on the available evidence, this alteration is classified as pathogenic. |
Baylor Genetics | RCV000679885 | SCV000807284 | pathogenic | KBG syndrome | 2017-09-01 | criteria provided, single submitter | clinical testing | This frameshift mutation is categorized as deleterious according to ACMG guidelines (PMID:18414213). It was found once in our laboratory as a de novo finding in a 4-year-old female with delays, hypotonia, anxiety, short stuture, atrial septal defect. |
Clinical Genetics and Genomics, |
RCV000256105 | SCV001450109 | likely pathogenic | not provided | 2015-01-19 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV000679885 | SCV001622826 | pathogenic | KBG syndrome | 2020-05-15 | criteria provided, single submitter | clinical testing | The de novo c.3770_3771del (p.Lys1257ArgfsTer25) variant identified in the ANKRD11 gene is the deletion of two nucleotides, resulting in the frameshift of the amino acid 1257/2664 (coding exon 9/13), and is predicted to lead to the premature termination of the protein approximately 25 amino acids downstream of the frameshift. This variant is absent from gnomAD(v3.0) suggesting it is not a common benign variant in the populations represented in that database. This variant is reported in ClinVar as Pathogenic (VarID: 265324) by two independent clinical labs who state the variant was identified de novo in affected individuals. The c.3770_3771del (p.Lys1257ArgfsTer25) variant has also been reported in the literature in a male with feeding difficulties, short stature, hyperopic astigmatism, hearing loss, and Autism Spectrum Disorder [PMID:28529015], and a female with KBG syndrome [PMID:31703437]. Given its presence de novo in this individual, its deleterious nature, absence in population databases, and observation in multiple affected individuals in the literature, the c.3770_3771del (p.Lys1257ArgfsTer25) variant identified in the ANKRD11 gene is reported here as Pathogenic. |
Genome Medicine, |
RCV000679885 | SCV002562750 | pathogenic | KBG syndrome | criteria provided, single submitter | clinical testing | KBG syndrome | |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV000679885 | SCV003807361 | pathogenic | KBG syndrome | 2022-07-06 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PVS1 very strong, PS4 strong, PM2 moderated, PM6 moderated |
Service de Génétique Moléculaire, |
RCV001257013 | SCV001433569 | likely pathogenic | Rare genetic intellectual disability | no assertion criteria provided | clinical testing | ||
Autoinflammatory diseases unit, |
RCV000679885 | SCV005381973 | pathogenic | KBG syndrome | 2024-06-24 | no assertion criteria provided | clinical testing |